Healthcare and pharmaceutical company Celesio has reported a 2.9% fall in sales to E2.54bn (£2.26bn) at its Patient and Consumer Solutions division for the first nine months of this year.

Growth in local currencies was 6.1%. The division’s EBITDA declined by 3.3% to E218.6m (£194.8m). In local currency terms, this corresponded to a 7.6% rise.

Pharmacy sales in the UK and Norway were strong. Together these two markets represented 72% of sales for the period.

Turnover at the mail order pharmacy division jumped 14.9% to E186.6m (£166.3m) over the period.

Topics